<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03718624</url>
  </required_header>
  <id_info>
    <org_study_id>HRA-G03</org_study_id>
    <nct_id>NCT03718624</nct_id>
  </id_info>
  <brief_title>A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells</brief_title>
  <official_title>A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of intraperitoneal and
      intravenous paclitaxel plus apatinib and S-1 in the conversion therapy of gastric cancer with
      positive exfoliative cancer cells
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 30, 2018</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0-resection rate</measure>
    <time_frame>within 3 weeks after surgery</time_frame>
    <description>There was no residual by the microscope</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Conversion to negative rate</measure>
    <time_frame>within 3 weeks after surgery</time_frame>
    <description>Exfoliative cytology positive gastric cancer conversion to negative rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5years</time_frame>
    <description>Baseline to measured date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>5years</time_frame>
    <description>Baseline to measured date of progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>5 years</time_frame>
    <description>Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.The number of Participants with adverse events will be recorded at each treatment visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Gastric Cancer With Positive Exfoliative Cancer Cells</condition>
  <arm_group>
    <arm_group_label>paclitaxel,apatinib and S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apatinib</intervention_name>
    <description>apatinib：500mg qd po, 28 days is a cycle. preoperative 2 cycles, 2 cycles after surgery.</description>
    <arm_group_label>paclitaxel,apatinib and S-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>Paclitaxel: intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 ，21 days is a cycle. preoperative 3 cycles, 3 cycles after surgery.</description>
    <arm_group_label>paclitaxel,apatinib and S-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>S-1： According to the body surface area, BSA &lt;1.25m2，40mg bid; 1.25m2≤BSA≤1.5m2，50mg bid; BSA &gt;1.5m2, 60mg bid. Take the medicine twice daily for 2 weeks, then suspend for 1 week. preoperative 3 cycles, 3 cycles after surgery.</description>
    <arm_group_label>paclitaxel,apatinib and S-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Untreated (e.g. chemotherapy, radiotherapy and other antitumor therapy);

          2. Age:18 to 70 years old;

          3. Man or female (except pregnant and lactating women);

          4. Confirmed to gastric adenocarcinoma;

          5. Proven gastric cancer of T stage was T3 and T4, and no distant metastasis was
             observed. The exfoliative cancer cells detection in peritoneal washes was positive;

          6. Blood cell count has to meet the following criteria:

             WBC≥3.5×109/L; ANC≥1.5×109/L; PLT≥100×109/L; HB≥90g/L;

          7. Liver/kidney function has to meet the following criteria:

             ALT and AST≤2.5*ULN TBIL&lt;1.5*ULN； Serum creatinine ≤1.5*ULN;

          8. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;

          9. Participants were willing to join in this study, good adherence and written informed
             consent.

        Exclusion Criteria:

          1. Patients with other malignant tumors within 5 years;

          2. Metastasis was found to be visible to the naked eye;

          3. It has serious or uncontrolled heart diseases and infections (Including atrial
             fibrillation, angina pectoris, cardiac insufficiency, ejection fraction less than 50%,
             poor-controlled hypertension and so on);

          4. History of psychiatric drugs abuse and can't quit or patients with mental disorders;

          5. Patients with severe or uncontrollable mental illness;

          6. Patients with tendency of gastrointestinal bleeding, including the following: a local
             active ulcerative lesions, and defecate occult blood (+ +).Has melena and hematemesis
             in two months;

          7. Pregnant or lactating women;

          8. It have serious harm to the patient's safety or affect the patients who have completed
             the research.

          9. The researchers think inappropriate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qun Zhao</last_name>
    <phone>13930162111</phone>
    <email>Zhaoqun516@126.com</email>
  </overall_contact>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>October 29, 2018</last_update_submitted>
  <last_update_submitted_qc>October 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University</investigator_affiliation>
    <investigator_full_name>Qun Zhao</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

